



Arcadia

B I O S C I E N C E S

Second-Quarter 2015 Business Results

August 10, 2015

Forward-looking statements



“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success; the company’s traits, commercial products, and collaborations; the company’s ability to manage the regulatory processes for its traits and commercial products, the company’s anticipated financial results; current and future products under development; additional collaboration agreements; the regulatory process; business and financial plans; and other non-historical facts. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance.

These risks and uncertainties include, but are not limited to: the company and its partners’ ability to develop commercial products incorporating its traits and complete the regulatory review process for such products; continued competition in seed traits and other products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; the company’s reliance on its collaborators to commercialize products incorporating its seed traits; the company’s future capital requirements and ability to satisfy its capital needs; the company’s exposure to various contingencies, including those related to intellectual property protection, success of field trials, regulatory compliance, the speed with which regulatory approvals are received, and public acceptance of biotechnology products; developments related to foreign governmental regulations, political climate, currencies and economies; successful operation of the company’s joint ventures; fluctuations in commodity prices; the company’s ability to obtain a significant portion of the increased value to farmers from products that incorporate its traits; and the effect of weather conditions, natural disasters and accidents on the agriculture business or the company’s facilities.

Further information on these and other factors that could affect the company’s financial results are included in filings it makes with the Securities and Exchange Commission from time to time, including the section entitled “Risk Factors” in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 and additional information that will be set forth in our Form 10-Q for the quarter ended June 30, 2015. These documents are or will be available on the SEC Filings section of the Investor Relations pages of the company’s website at www.arcadiabio.com. All information provided in this presentation and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.

Key financial results



	Second Quarter			First Half		
	2015	2014	% Increase/ (Decrease)	2015	2014	% Increase/ (Decrease)
Total revenues	1,430	1,305	10%	2,245	2,682	(16%)
Cost of product revenues	106	46	130%	162	137	18%
R&D expense	2,086	2,275	(8%)	3,918	4,258	(8%)
SG&A expense	2,785	3,983	(30%)	5,423	5,867	(8%)
Loss from operations	(3,547)	(4,999)	(29%)	(7,258)	(7,580)	(4%)
Net loss and comprehensive loss	(3,677)	(5,811)	(37%)	(9,480)	(9,287)	2%
Net loss attributable to common stockholders	(4,556)	(6,329)	(28%)	(12,251)	(9,805)	25%
Net loss per share	(0.19)	(3.08)	N/A	(0.94)	(4.77)	N/A
Cash flows from operating activities				(6,582)	(8,423)	(22%)
Basic and diluted shares outstanding	23,775,368	2,056,559		12,985,332	2,056,559	

*\$K, except share and per share data
Unaudited*



Revenue

	Second Quarter			First Half		
	2015	2014	% Increase/ (Decrease)	2015	2014	% Increase/ (Decrease)
Product revenue	179	65	175%	260	199	31%
License revenue	401	195	106%	559	371	51%
Contract research and governmental grants	850	1,045	(19%)	1,426	2,112	(32%)
Total revenues	1,430	1,305	10%	2,245	2,682	(16%)

\$K; Unaudited

First-half revenue mix comparison:

- Product revenue
- License revenue
- Contract research and government grants





Operating expenses

	Second Quarter			First Half		
	2015	2014	% Increase/ (Decrease)	2015	2014	% Increase/ (Decrease)
Cost of product revenues	106	46	130%	162	137	18%
R&D expense	2,086	2,275	(8%)	3,918	4,258	(8%)
SG&A expense	2,785	3,983	(30%)	5,423	5,867	(8%)
Total operating expenses	4,977	6,304	(21%)	9,503	10,262	(7%)

\$K; Unaudited

First-half expense mix comparison:

- Cost of product revenues
- R&D expense
- SG&A expense



Late-stage portfolio with 13 products in Phase 3 of development or later



Program	Crop	Collaborator(s)	Phase	D	1	2	3	4	C	Key markets	
			Months	24-48	12-24	12-24	12-24	12-36			
Productivity traits: Designed to increase crop yields and income through improved input efficiency and environmental stress tolerance											
				Probability of success ¹							
				5%	25%	50%	75%	90%			
Nitrogen Use Efficiency (NUE)	Wheat	Limagrain, Mahyco, CSIRO, ACPFG		█	█	█	█			Global	
	Rice	Mahyco, AATF		█	█	█	█			Asia	
	Canola	-		█	█	█	█			North America, Asia	
	Barley	-		█	█	█	█			North America, Australia	
Water Use Efficiency (WUE) and Drought Tolerance (DT)	Soybean (DT)	Verdeca		█	█	█	█	█		Americas, Asia	
	Wheat (DT)	Bioceres		█	█	█	█			Global	
Salinity Tolerance (ST)	Rice	Mahyco		█	█	█	█			Asia	
Herbicide Tolerance²	Wheat	Confidential		█	█	█	█			Global	
Trait Stacks											
NUE/WUE/ST	Rice	AATF		█	█	█	█			Asia	
Product quality traits: Designed to increase the value of harvested products											
GLA Oil	Safflower	Abbott		█	█	█	█	█	█	North America, Asia	
Resistant Starch²	Wheat	-		█	█	█	█	█		Global	
Post Harvest Quality²	Tomato	Bioseed		█	█	█	█			Asia, North America	
ARA Oil	Safflower	Abbott, DuPont Pioneer		█	█	█	█			North America, Asia	

Note: Phase: D=Discovery; 1=Proof of Concept; 2=Greenhouse / Early Field Trials; 3=Additional Field Trials / Product Development; 4=Regulatory / Pre-Commercial; C=Commercialized

¹ Based on industry standard probabilities

² Non-GM

Regulatory approvals and commercial partnerships continue to advance pipeline

Regulatory advancements



Regulatory approval of stress-tolerant soybeans by CONABIA in Argentina



US FDA Early Food Safety Evaluation for NUE trait in all crops



US FDA approval of GLA safflower oilseed meal in animal feed

Commercial advancements



Verdeca collaboration with TMG to advance breeding of stress-tolerant soybeans in South America



Verdeca collaboration with Dow AgroSciences to advance yield traits in soybeans in South America



Phytola research partnership to develop soybean varieties with increased oil content


NUE rice demonstrates average yield increase of 27%

Nitrogen Use Efficiency – Rice						Market Channel	Data Notes
DEVELOPMENT PHASE /SUCCESS PROBABILITY						<ul style="list-style-type: none"> Major seed company in India; partially owned by Monsanto Key partner since 2007 	<ul style="list-style-type: none"> NEW: Fourth year of independent field testing demonstrated average yield increase of at least 27% in multiple environments
D	1	2	3	4	C		
24-48 mo	12-24 mo	12-24 mo	12-24 mo	12-36 mo			
5%	25%	50%	75%				

NUE Rice Field Trial Results


Production Environment	N Rate (% normal)	NUE Rice Mean (% yield increase)
Lowland	0%	25%
	50%	26%
	100%	25%
Upland	50%	30%
	Mean	27%

Based on 3 years of field trials conducted by the International Center for Tropical Agriculture (CIAT)



Source: FAO, CIAT, Company information

Open architecture maximizes technology access and global market penetration



Source: Company information, Phillips McDougall, Seed Industry June 2014.